XORTX Therapeutics Inc. (NASDAQ:XRTX – Get Free Report) saw a significant drop in short interest in October. As of October 30th, there was short interest totaling 122,511 shares, a drop of 48.3% from the October 15th total of 237,048 shares. Based on an average daily volume of 58,359 shares, the short-interest ratio is currently 2.1 days. Currently, 7.2% of the company’s stock are sold short.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of XORTX Therapeutics in a report on Monday, September 21st. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, XORTX Therapeutics presently has an average rating of “Sell”.
Check Out Our Latest Report on XORTX Therapeutics
XORTX Therapeutics Stock Down 2.8%
Shares of NASDAQ:XRTX opened at $1.01 on Tuesday. The firm has a market capitalization of $1.84 million, a PE ratio of -0.44 and a beta of 0.83. XORTX Therapeutics has a twelve month low of $0.82 and a twelve month high of $3.60. The company has a 50-day moving average price of $1.44 and a two-hundred day moving average price of $2.02.
XORTX Therapeutics (NASDAQ:XRTX – Get Free Report) last posted its quarterly earnings results on Saturday, November 14th. The technology company reported ($0.21) earnings per share (EPS) for the quarter.
XORTX Therapeutics Company Profile
XORTX Therapeutics Inc. is a clinical-stage biotechnology company headquartered in Calgary, Alberta. It develops treatments for progressive kidney diseases, with a focus on conditions that can lead to declining kidney function. The company’s research programs include XRx-008 for autosomal dominant polycystic kidney disease, XRx-101 for acute kidney injury, and XRx-225 for diabetic nephropathy. These programs are investigational and are not marketed therapies. XORTX’s approach focuses on purine metabolism and the enzyme xanthine oxidase, which the company is studying as a target for reducing processes associated with kidney injury and disease progression.
See Also
- Five stocks we like better than XORTX Therapeutics
- 3 Stocks in an Overlooked Corner of Infrastructure With Hundreds of Billions at Stake
- Tyson Foods’ 10% Surge Puts a Breakout in Sight, But Wall Street Remains Cautious
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
Receive News & Ratings for XORTX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XORTX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
